Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.36
- Piotroski Score 1.00
- Grade Neutral
- Symbol (ARPO)
- Company Aerpio Pharmaceuticals, Inc.
- Price $2.20
- Changes Percentage (-0.9%)
- Change -$0.02
- Day Low $2.16
- Day High $2.30
- Year High $49.80
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-36,917,000
Income Statement
Quarterly
Annual
Latest News of ARPO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Grass Valley residents want carports back after losing them in 2023 winter storms
Residents in Grass Valley are demanding the return of carports at three apartment complexes damaged in winter storms. The Cascade Housing Association faces pressure from the City Council to rebuild th...
By CBS News | 1 week ago -
'Marpole rapist' granted full parole, victims' families concerned about lack of notice - BC | Globalnews.ca
Gary Jagur Singh, the "Marpole Rapist," has been granted full parole after rehabilitation efforts and evaluation, despite concerns about informing the public. Singh, convicted of sexually assaulting 1...
By Global News | 3 weeks ago -
Rachel Roddy's recipe for hazelnut and walnut cake with fig compote and mascarpone | A kitchen in Rome
A walnut cake with added hazelnuts and fig compote recipe is shared, along with insights on a collection of well-loved cookbooks. The cake is moist and tender, perfect with seasonal fruit. The recipe ...
By The Guardian | 1 month ago
